Randomized controlled trial of antibiotic prophylaxis regimens for transrectal ultrasound-guided prostate biopsy

Chinese Medical Journal

Volumn 125, Issue 14, 2012, Pages 2432-2435

  Chan, Eddie Shu Yin ^a   Lo, Ka Lun ^a   Ng, Chi Fai ^a   Hou, See Ming ^a   Yip, Sidney Kam Hung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antibiotic; Biopsy; Complications; Prophylaxis; Prostate

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHILL; DRUG EFFICACY; ESCHERICHIA COLI; FEVER; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INCIDENCE; INFECTION; KLEBSIELLA; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; PROSTATE BIOPSY; RANDOMIZED CONTROLLED TRIAL; RIGOR; TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BIOPSY, NEEDLE; CIPROFLOXACIN; CLAVULANIC ACID; HUMANS; MALE; PROSTATE; RECTUM;

EID: 84864188123     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.14.006     Document Type: Article

References (21)

1. Yip SK, Sim HG. Robotic radical prostatectomy in East Asia: development, surgical results and challenges. Curr Opin Urol 2010; 20: 80-85.
2. Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy-Are fluoroquinolones still effective prophylaxis? J Urol 2008; 179: 952-955.
3. Miura T, Tanaka K, Shigemura K, Nakano Y, Takenaka A, Fujisawa M. Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. Int J Urol 2008; 15: 457-459.
4. Ng CF, Chan SY. The incidence of fluoroquinolone resistant infections after prostate biopsy-Are fluoroquinolones still effective prophylaxis? J Urol 2008; 180: 1570-1571.
5. Brown R. Bacteremia and bacteriuria after transrectal prostate biopsy. Urology 1981; 18: 145-148.
6. NHS (National Health Service). Diagnostic value of systematic prostate biopsy method in the investigation of prostate cancer. (Accessed 2010 at http://www.cancerscreening.nhs.uk/prostate/pcbs01.html)
7. Melekos MD. Efficacy of prophylactic antimicrobial regimens in preventing infectious complications after transrectal biopsy of the prostate. Int Urol Nephro 1990; 22: 257-262.
8. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000; 85: 682-685.
9. Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998; 52: 552-558.
10. Sieber PR, Rommel FM, Theodoran CG, Hong RD, Del Terzo MA. Contemporary prostate biopsy complication rates in community-based urology practice. Urology 2007; 70: 498-500.
11. Department of Health, The Government of Hong Kong SAR. Antibiotic resistance patterns of bacteria isolated from urine specimens. (Accessed March 5, 2010 at http://www.chp.gov.hk/en/data/4/10/26/45/86.html)
12. Shandera KC, Thibault GP, Deshon GE. Variability in patient preparation for prostate biopsy among American urologists. Urology 1998; 52: 644-646.
13. Schaeffer AJ, Montorsi F, Scattoni V, Perroncel R, Song J, Haverstock DC, et al. Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate. BJU Int 2007; 100: 51-57.
14. Lange D, Zappavigna C, Hamidizadeh R, Goldenberg SL, Paterson RF, Chew BH. Bacterial sepsis after prostate biopsy-A new perspective. Urology 2009; 74: 1200-1205.
15. Tal R, Livne PM, Lask DM, Baniel J. Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy. J Urol 2003; 169: 1762-1765.
16. Andreu A, Alós JI, Gobernado M, Marco F, de la Rosa M, García-Rodríguez JA. Etiology and antimicrobial susceptibility among uropathogens causing communityacquired lower urinary tract infections: a nationwide surveillance study. Enferm Infecc Microbiol Clin 2005; 23: 4-9.
17. Young JL, Liss MA, Szabo RJ. Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology 2009; 74: 332-338.
18. Hadway P, Barrett LK, Waghorn DJ, Hasan K, Bdesha A, Haldar N, et al. Urosepsis and bacteraemia caused by antibiotic-resistant organisms after transrectal ultrasonography-guided prostate biopsy. BJU Int 2009; 104: 1556-1558.
19. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schröder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60: 826-830.
20. Simsir A, Kismali E, Mammadov R, Gunaydin G, Cal C. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int 2010; 84: 395-399.
21. Chiang IN, Chang SJ, Pu YS, Huang KH, Yu HJ, Huang CY. Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in Taiwan. J Formos Med Assoc 2007; 106: 929-934.